0.20Open0.20Pre Close0 Volume45 Open Interest8.00Strike Price0.00Turnover281.82%IV107.59%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier17DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type0.1951Delta0.1153Gamma19.75Leverage Ratio-0.0196Theta0.0003Rho3.85Eff Leverage0.0023Vega
Geron Stock Discussion
Almost low enough
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
No comment yet